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A  form of  chronic nephritis  characterized by  mesangial  proliferation  and 
thickened capillary walls is often accompanied by low serum complement levels. 
Hypocomplementemia is primarily attributable to the low serum concentration 
of C3  (1, 2). The first three reacting components of the classical complement 
pathway, C1, C2, and C4, are usually within normal range (3). 
We have previously postulated that the  hypocomplementemia is caused by 
the C3 nephritic factor (C3NeF),  ~ which may be found in the serum of these 
patients  and  which  activates  the  complement system  through  an  alternate 
pathway  (4--6).  In fact, it has recently been demonstrated that the action of 
C3NeF in vitro requires the C3 proactivator (C3PA)  (7). Evidence indicating 
that activation of complement does occur in vivo includes the demonstration 
of C3d (a2D) (8), an enzymatic cleavage product of C3, and the finding of low 
levels of properdin and C3PA in the serum of these patients (7, 9). Further, C3 
metabolic studies have revealed an increased fractional catabolic rate, and in 
some patients also a decreased synthetic rate (10). 
We now wish to report the method of isolation of C3NeF and the delineation 
of its mechanism of action. C3NeF isolated from the plasma of three different 
patients  with  hypocomplementemic chronic  glomerulonephriti  s  (HCG)  was 
found to be distinct from immunoglobulins, and to effect C3 cleavage through 
recruitment of the entire C3 activator or properdin (P) system. 
* This is publication no. 776 from the Department of Experimental Pathology, Scripps 
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1  Abbreviatior6s used in this paper: AI, anaphylatoxin inactivator; AT, anaphylatoxin; CM, 
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Materials and Methods 
Serum and Plasma.--Serum and plasma were obtained from three patients with HCG at 
the Children's Hospital Research Foundation, Cincinnati, Ohio. 
Method of Isolation  of C3NeF. Triethylaminoethyl (TEAE)-cellulose  chromatography: 25 
ml of serum were dialyzed against 0.02 M  phosphate buffer, pH  7.0,  overnight. The  serum 
was applied to a 4  X  18-era column containing TEAE-cellulose which had been equilibrated 
with the same buffer. The C3-converting activity was found in fractions corresponding to 
the first protein peak.  This material was concentrated by  ultrafiltration to approximately 
2 ml in an Amicon concentration device using a  XM 50 ultrafilter (Amicon Corp., Lexing- 
ton, Mass.). At this stage a radiolabel was introduced in order to obtain protein elution pro- 
files after subsequent separation procedures. A portion of the material was labeled with 1251 
by the chloramine-T method according to McConahey and Dixon  (11). The specific radioac- 
tivity was approximately 3.236 cpm/#g of protein. 
Carboxymethyl (CM)  Sephadex C50 chromatography:  The active pool from  the TEAE- 
cellulose column containing 30 mg of protein was dialyzed against 0.02 M  phosphate buffer, 
pH  6.0,  and  then applied  to a  1.7  X  20 cm  CM  Sephadex C50 column  (Pharmacia Fine 
Chemicals, Inc., Piscataway, N.  J.)  equilibrated with the same buffer. The C3-converting 
activity was found in the early effluent, and the fractions were pooled and concentrated. The 
adsorbed protein was eluted with a NaC1 concentration gradient from a conductance of 15.0- 
30 mmho/cm. 
Molecular sieve chromatography using Sephadex G-200:  The  active  pool  from  the  CM 
Sepbadex step was concentrated to 1 ml containing 13 mg protein and applied to a  1 X  30 
cm Sephadex G-200 column (Pharmacia Fine Chemicals, Inc.)  equilibrated with phosphate 
buffer, pH 7.5, ionic strength 0.2. The active material was eluted together with 7S T-globulin. 
Immune adsorption of immunoglobulin:  10 ml of polyvalent goat antiserum to T-globulin 
was mixed with 10 ml of 0.2 M  acetate buffer, pH 5.2, and the protein was insolubilized by 
addition of 1.6 ml of ethyl chloroformate (12).  Mter thorough washing the solid adsorbent 
was suspended in 2 ml of the active C3NeF pool from the gel filtration step, containing 0.05 
M EDTA. The suspension was kept overnight at 4°C and then subjected to centrifugation at 
20,000 rpm for 1 h in a no. 40 rotor and a  Spinco L2 centrifuge (Beckman Instruments, Inc., 
Spinco Div., Palo Alto, Calif.). The recovered supernatent was dialyzed against 2 X  10 liters 
of phosphate buffer, pH 7.0, ionic strength 0.05. 
Elution of adsorbed T-globulin:  The immune adsorbent was washed with 2 X  50-ml phos- 
phate buffer, pH 7.0, ionic strength 0.05, and washed once with 50 ml of 1 M  NaC1. The ad- 
sorbed protein was then eluted with 3 X  10 ml of 4 M potassium iodide in 0.01 M Tris buffer, 
pH 8.2,  and 0.1%  bovine serum albumin (13).  The eluted protein was concentrated in an 
Amicon concentration device using a XM 50 ultrafilter (Amicon Corp.). 
C3NeF Assay.--Presence  of C3NeF in serum or serum fractions was ascertained by three 
different criteria:  (a)  Detection of C3  and C3PA  conversion by immunoeleetrophoresis in 
mixtures of 25/~1 of the C3NeF-containing sample with 100/zl of normal human serum (NHS) 
incubated at 37°C for 30 rain; (b) measurement of whole human complement hemolytic ac- 
tivity present in the same mixtures  (14); and  (c)  the ability of C3NeF  to initiate lysis of 
glutathione-treated human erythroeytes (GSHE) in presence of normal serum  according  to 
a method to be describedY To prevent C3 cleavage due to contaminating endotoxin  or  T- 
globulin aggregates,  the  C3NeF  samples were  subjected  to ultracentrifugation for 1 h  at 
49,000  rpm before the assay. 
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ImmunochemCxal Analysis.IImmunoelectrophoresis was performed using 2% agar in bar- 
bital buffer, pI-I 8.6, with 0.02 M EDTA. For the analysis of the C3NeF preparations by the 
double diffusion-in-gel method, rabbit antisera to IgG3, Fc, kappa, lambda, and C3NeF were 
used. 
Zone Ele~trophoresis.--1.5 ml of plasma from a patient with chronic nephritis and hypo- 
complementemia were separated by electrophoresis on Pevikon blocks in barbital buffer, pH 
8.6,  ionic strength 0.05,  for 16 h  at 4°C and 3.5 V/cm.  Microzone dectrophoresis was per- 
formed on cellulose acetate strips in a  Beckman microzone electrophoresis apparatus,  Model 
R101, using Beckman barbital buffer B-2  (Beckman Instruments,  Inc.,  Spinco  Div.,  Palo 
Alto, Calif.), pI-I 8.5, ionic strength 0.075 and 250 V for 20 min at 20°C. 
Sucrose Density Gradient Ultracentrifugation.--Linear  sucrose density gradients  (7-31%) 
were produced  with the  Buchler automatic  density gradient device (Buehler Instruments 
Div., Nuclear-Chicago Corp., Fort Lee, N. J.). Ultracentrifugation was performed for 17 h at 
35,000  rpm. and 4°C in a Spinco L-2 machine employing an SW 39  rotor  (Beckman Instru- 
ments, Inc., Spinco Div.). Fractions were obtained using a Buchier gradient fractionafion de- 
vice (Buchler Instruments Div., Nuclear-Chicago Corp.). For s-rate determinations C l q (1 IS) 
and bovine serum albumin (4.4S) were used as reference substances. 
Sera Deficient in Various Serum Proteins.--C2-deficient  serum was kindly supplied by Dr. 
Vincent Agnello, The Rockefeller University, New York. Serum reagents deficient in P, C3PA 
or C3 proactivator convertase (C3PAse)  were prepared according to GStze and Mtiller-Eber- 
hard  (15).  Nephritic serum was rendered deficient in C3NeF using a solidified antiserum to 
C3NeF. The same immune adsorbent was used for treatment of NHS. 
Generation and Measurement of Anaphylatoxins  (AT).--48 #g of a C3NeF preparation was 
incubated at 37°C for 30 rain with NHS depleted of the anaphylatoxin inactivator (AI) by 
immune adsorption  (16).  C3a and  C5a activity was demonstrated  by the guinea pig ileum 
test as described  (17). 
RESULTS 
Purification of CJNeF.--Serum from patients with HCG having high C3NeF 
activity was used. The starting material (25 ml) was chromatographed on a 
TEAE-cellulose column using 0.02 M phosphate buffer, pH 7.0 (Fig.  1). The 
C3-converting activity was found in the early column fractions together with 
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Fro.  1.  First step  of isolation procedure of C3NeF. TEAE-cellulose chromatography  of 
serum from a patient with HCG using 0.02  M  phosphate buffer, pH 7.0.  Only the elution 
profile of the nonadsorbed  protein is shown. The bar indicates the pool of C3NeF activity 
containing fractions. 1252  NEPHRITIC FACTOR 
IgG, Clq, and P. The protein content of these fractions was 1.8 % of the starting 
material.  The  active material was further purified  by chromatography on a 
CM  Sephadex  C50  column  (Fig.  2).  The  C3-converting  activity  was eluted 
together with IgG, but preceding elution of Clq and of P. The next step con- 
sisted of molecular sieve chromatography as shown in Fig. 3. Again, the activity 
was eluted together with IgG which accounted for 75 % of the protein contained 
in  the  active fractions.  In  order  to  ascertain  as  to  whether  the  C3-cleaving 
activity was a property of IgG, the pool was treated with insolubilized poly- 
valent antihuman immunoglobulin. After immune adsorption the active mate- 
rial remained in the supernate. The immunoglobulins eluted from the adsorbent 
with 4  M  KI were inactive in the  C3NeF assay. The yield, purification,  and 
specific activity are listed in Table I. The absolute increase in C3NeF activity 
during  the first fractionation procedure may be due to an inhibiting  effect of 
unknown nature in whole serum. The degree of purification was approximately 
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FIC. 2.  Second step of isolation of C3NeF. CM Sephadex chromatography of C3NeF con- 
taining pool of the first chromatographic step (Fig. 1). The C3NeF activity was eluted with 
0.02 M phosphate buffer, pH 6 (left panel).  Bar indicates C3NeF containing fractions whice 
were pooled for further separation. The right panel shows elution of the adsorbed protein, 
including P, by sodium chloride concentration gradient. P was detected immunochemically. 
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FIG. 3. Third step of isolation of C3NeF. Molecular sieve chromatography on Sephadex 
G-200 of C3NeF containing pool from the second chromatographic step (Fig. 2). Phosphate 
buffer, pH 7.5, ionic strength 0.2, was used. VALLOTA ET AL.  1253 
1,000-fold,  and  the  final  yield  15-25%.  Assuming  that  90%  of the  isolated 
protein  represents  C3NeF,  its  concentration  in  the  original  serum  may be 
calculated to be 55-95/~g/ml. 
Immunochemical  and Physicochemical  Characterization  of C3NeF.--The  iso- 
lated active material before and after the immune  adsorption step was  sub- 
jected to  double  diffusion-in-gel analysis  using  antiwhole human  serum  and 
monospecific antisera to IgA, IgM, IgG3, the Fc and F(ab)~2  fragments, and 
kappa and lambda chains. As shown in Fig. 4, precipitin lines formed between 
anti-IgG3,  -Fc,  -kappa,  and -lambda  only with  the material before immune 
adsorption (st) and with the reference proteins, Cohn fraction II (CII) (Mann 
Research Laboratories Inc., New York), IgG3, or IgG2. The active material 
after immune adsorption failed to develop a precipitin line with these antisera 
and with antisera to IgA, IgM, and F(aby2. Two of three antisera  to whole 
TABLE I 
Purification of C3NeF from Serum 
Material  Volume  Protein  Activity  Purification 
ml  mg  U*  U/mg 
Serum  25  1,625  250  0.15 
TEAE pool  2  30  416  13.86 
CM pool  1  13  371  28.54 
G200 pool  1  1.6  83  51.86 
After IA  0.5  0.4  62.5  156.25 
Final Purification:  1,041  X 
Yield:  15-25% 
* 1 U, C3NeF activity required for 100% inactivation of hemolytic activity in  100/zl 
NHS in 30 rain at 37°C. 
human serum (Behringwerke AG, Marburg, West Germany) gave a  negative 
precipitin reaction under the conditions used.  The third antiserum,  made in 
this laboratory, permitted detection of one or more weak precipitin lines. 
The nonidentity of C3NeF with IgG was  further demonstrated by Ouch- 
terlony  analysis  with  an  antiserum  raised  with  one  of  the  preparations  of 
C3NeF. When a preparation of C3NeF containing IgG was analyzed with anti- 
C3NeF  and  anti-IgG  the  resulting  precipitin  lines  clearly  crossed  (Fig.  5). 
Antiserum produced to C3NeF of one p~tient also reacted with C3NeF of the 
other two patients. 
Isolated C3NeF behaved as "y-globulin  on cellulose acetate electrophoresis 
(Fig. 6). When whole nephritic serum was subjected to Pevikon block electro- 
phoresis,  C3NeF  activity was  also detected in  the "y-globulin  fraction. Both 
C3NeF activity and the antigen detected by anti-C3NeF had similar distribu- 
tions (Fig. 7). 1254  NEPHRITIC FACTOR 
Dose-Response of C3NeF Activity.--C3NeF  activity was measured by deter- 
mining the degree of reduction of hemolytic activity in NHS after incubation 
with  C3NeF.  When  increasing  quantiUes  of isolated  C3NeF  were  incubated 
with  a  constant volume of serum,  a  linear dose response was obtained,  Fig. 8 
shows  the  plot  of micrograms  of  C3NeF/100  /A  of NHS  vs.  the  percent  of 
residual hemolytic activity in the NHS sample. 
Fro.  4.  Immunochemical analysis of C3NeF before (St.) and after (Abs.) absorption with 
solidified antihuman immunoglobulin. The center well contains antiserum  to IgG3 (aG3), Fc 
fragment  (Fc), kappa chain  (ak), and lambda  chain  (aX). Cohn fraction  II (C.II) was used 
in two different concentrations,  1 mg/ml and 0.1 mg/ml, respectively. Protein eluted  from 
the immune adsorbent  with 4 M KI:EL. 
FIO. 5.  Analysis of crude C3NeF with  anti-IgG and  an antiserum  prepared  with highly 
purified C3NeF. The antigen recognized by anti-C3NeF is distinct from the IgG contaminant. VALLOTA ET  AL.  1255 
Mechanism  of  Complement Inactivation  by  C3NeF.--Addition  of  isolated 
C3NeF to genetically C2-deficient serum which had an unimpaired function of 
the  alternate  pathway  resulted  in  efficient cleavage  of  C3  and  C3PA.  The 
immunoelectrophoretic patterns shown in Fig. 9 are representative for normal 
FIG.  6.  Electrophoretic behavior of isolated C3NeF after immune adsorption on cellulose 
acetate at pH 8.5. For comparison, the pattern of whole human serum is shown. 
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FIC.  7.  Localization of C3NeF in fractions of whole human serum after zone electrophoresis 
on a Pevikon block at pH 8.6. 
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FIG. 8.  Quantitative relation between the amount of isolated C3NeF added to NHS and 
the resultant reduction in hemolytic activity. 6.4 Atg of C3NeF caused 100% loss of the activity 
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and C2-deficient serum. The results indicate that C3NeF action of C3 does not 
require C2 but involves C3PA.  Since C3PA was affected by C3NeF in normal 
and in C2-deficient serum, we tested whether it forms a  complex with a normal 
serum protein such as C3PA in analogy to cobra venom factor. 12q-radiolabeled 
C3NeF, before immune adsorption, was added to NHS  and the mixture incu- 
bated  for  5  rain  at  37°C.  Marker  substances  for  s-rate  determinations were 
added and the mixtures subjected to sucrose density gradient ultracentrifuga- 
tion. For comparison,  C3NeF not in mixture with  NHS, was examined under 
the  same  conditions.  Fig.  10  shows  that  C3NeF  alone  and  C3NeF  added  to 
F16.  9.  Immunoelectrophoretic demonstration of C3  and  C3PA conversion  by C3NeF. 
Pattern is representative for normal and  C2-deficient  human serum.  A  and C,  untreated 
serum;  and B and D, serum incubated with C3NeF. A and B were developed with anti-C3, 
and C and D with anti-C3PA. 
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FiG.  10.  Zone  ultracentrifugafion of C3NeF in  sucrose  density gradient.  Upper panel, 
C3NeF alone; lower panel, C3NeF in NHS. Comparison of velocity of C3NeF under both 
conditions indicates lack of complex formation with normal serum protein. VALLOTA  ET  AL.  !257 
serum sediment with an identical velocity, approximately 7S.  The result indi- 
cated that the factor does not enter into a complex with C3PA. Isolated C3NeF 
was unable  to cause C3  conversion in  serum depleted  of either P,  C3PA,  or 
C3PAse. Similarly, it failed to cause C3PA conversion in serum depleted of P, 
C3,  or  C3PAse.  The requirement  of  C3  iu  the  C3PA  cleavage reaction  was 
demonstrated using serum containing less than 5 %  of the normal amount of 
C3. Whereas isolated C3NeF had no effect on C3PA in this serum, it caused 
C3PA  conversion after addition  of isolated  C3  to restore  a  normal  C3  level. 
The results are summarized in Table II. According to these data C3NeF acts 
exclusively through the alternate pathway of complement activation. 
Generation  of A T  by  C3NeF in  Serum Depleted  of the A I.--Incubation  of 
isolated C3NeF with NHS, which had been rendered deficient in AI, invariably 
resulted in appearance of AT activity. The active material appeared to consist 
of both C3a and C5a since the guinea pig ileum became resistant  to challenge 
by isolated human C3a and C5a (Fig. 11). 
Occurrence of a C3NeF Analogue in Normal Serum and its Possible Function.- 
Three  different  HCG  sera  were  treated  with  solidified  antiserum  to  highly 
purified  C3NeF.  This  treatment  resulted  in removal  of C3NeF  activity  and 
antigen.  Ouchterlony  analysis  of multiple  normal  sera  invariably  revealed  a 
TABLE II 
C3 and C3PA Conversion by C3NeF  in Sera Deficient in Various Serum Proteins 
Serum depleted in  addition 
conversion 
C3  C3PA 
0  0  0  0 
0  C3NeF*  85  70 
C2  C3NeF  70  50 
P  C3NeF  0  0 
C3PA  C3NeF  0  0 
C3PAse  C3NeF  0  0 
C3  C3NeF  0  0 
* C3NeF preparation  no. 5, 6 #g of C3NeF/100/~1 of serum. 
H C3NeF  C3a  HC5a  H 
+NHS* 
Fla.  11.  Demonstration  of AT activity in serum  previously  depleted  of the AI (NHS) 
and then treated for 30 min at 37°C with isolated C3NeF. H, response to histamine. 1258  NEPHRITIC  FACTOR 
weak but definite precipitin reaction with anti-C3NeF. Treatment of several 
different normal  sera  with  the  solid  anti-C3NeF  immune  adsorbent  led  to 
disappearance of the antigen detected by anti-C3NeF and to an impairment 
of the function of the alternate pathway. Lysis of glutathione-treated human 
erythrocytes by inulin-activated serum became negative. When a  fraction of 
normal serum containing the C3NeF antigen was added to the anti-C3NeF- 
depleted serum, the lyric capacity was restored. 
DISCUSSION 
At present the origin and nature as well as the possible role of the nephritic 
factor in  the pathogenesis of renal  disease is not well understood. Evidence 
obtained in other laboratories appears to relate the anticomplementary factor 
found in HCG to the immunoglobulins. 
Thompson (18) prepared a fraction from HCG serum which contained C3- 
cleaving activity when added to normal serum and which was rich in IgG3. 
The notion that IgG3 might have nephritic factor activity was strengthened 
by the observation that the activity was removable with insolubilized rabbit 
antihuman IgG. 
Day et al. (19) described a patient with focal glomerulonephritis associated 
with an in vitro conversion of C3 which was found to be dependent on cold, 
metal ions, and IgA. These authors postulated that C3 inactivation was effected 
by the patient's IgA and by activation of the alternate pathway. In kidney 
biopsies C3, P, and IgA were detectable, whereas IgG, IgM, and C3PA were 
not observed. 
The  above observations are  consistent with the hypothesis that  the  anti- 
complementary activity in nephritic serum may reside in immunoglobulins. 
In contrast, the present study indicates the clear distinctness of isolated ne- 
phritic  factor  from  immunoglobulins.  This  was  shown  for  nephritic  factor 
from  three  different patients.  Adsorption  of partially purified  C3NeF  with 
solidified anti-Ig removed all immunochemically detectable immunoglobulins 
without removing C3NeF activity. In fact, the specific  activity in  terms of 
units per milligram increased  threefold by the  adsorption step.  Further,  an 
antiserum prepared  to highly purified C3NeF did not react with human Ig, 
but gave  a  positive precipitin reaction  with  C3NeF  and  C3NeF-containing 
serum fractions. This antiserum also removed C3NeF activity from nephritic 
sera. Although it was prepared to an individual C3NeF, it reacted with that of 
other patients, suggesting that C3NeF is an entity which is qualitatively similar 
or identical in different patients. These observations need not contradict  the 
work of other investigators, because other nephritides may well be  associated 
with anticomplementary serum factors which constitute immunoglobulin. 
When  C3NeF  was  first  described,  the  possibility was  considered  that  it 
might constitute a  mammalian analogue to  cobra venom factor. As  such  it 
should enter into a  complex with C3PA when added to normal serum.  The VALLOTA ET  AL.  1259 
present experiments have precluded this possibility, however, they have shown 
a dependence of C3NeF action on the presence of C3PA, as was also shown by 
others (7). In addition, we demonstrated the requirement of P, C3, and C3PAse. 
Since anti-C3NeF recognized  an antigen in NHS, the possibility was raised 
that normal  serum contains an inactive C3NeF analogue which may be the 
precursor of C3NeF. Because removal of this antigen  impaired  the alternate 
pathway, it probably constitutes one of the heretofore unrecognized components 
of the P  system. The dependence of nephritic factor on P, C3,  C3PAse, and 
C3PA and the failure of inulin  to activate normal  serum,  treated with anti- 
C3NeF, strongly suggest that the normal C3NeF analogue precedes P  in the 
molecular events of the alternate pathway. As such it may represent the com- 
ponent which directly interacts with activating substances and which triggers 
the P pathway. Fig. 12 presents our current concept of the alternate pathway 
which must be regarded as tentative. Work is underway to establish the func- 
tion of the normal C3NeF analogue. 
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FIG.  12.  Schematic representation  of hypothesis linking nephritic factor  (C3NeF)  to a 
normal component of the P pathway (IF). According to this hypothesis, activating substances 
confer activity on IF (rF) which resembles that of C3NeF. Probably in cooperation with an 
as yet unidentified serum factor (X), rF activates P  and thus sets in motion the events in- 
volving C3, C3PAse, and C3PA that have been described in detail elsewhere (15). 
SUMMARY 
Nephritic factor  (C3NeF)  has been isolated from plasma of patients  with 
hypocomplementemic chronic  glomerulonephritis  (HCG) by ion exchange  and 
molecular  sieve  chromatography.  This  material  was  further  treated  with 
solidified anti-Ig antiserum. The purified material failed to react with antiserum 
to human IgG, IgG3, Fab, Fc, and kappa and lambda chains, but retained full 1260  NEPHRITIC  FACTOR 
C3NeF activity. The nonidentity of C3NeF with IgG was further demonstrated 
by Ouchterlony analysis using anti-IgG and anti-C3NeF. Isolated C3NeF was 
found to be a protein with a  sedimentation coefficient of 7S  and a  tool wt of 
150,000  daltons, which on microzone electrophoresis and gel electrophoresis at 
pH 8.6 behaved as a "~,-globulin. C3NeF is not a  Clq precipitin and does not 
activate  the  classical  complement pathway.  Unlike  cobra  venom  factor,  it 
failed to enter into  a  complex with  C3 proactivator (C3PA)  when incubated 
with normal human serum (NHS) and then subjected to sucrose density gradi- 
ent ultracentrifugation.  The action of isolated  C3NeF on C3  requires  C3PA, 
C3PA  convertase  (C3PAse),  and properdin  (P).  Similarly~  C3PA  conversion 
by C3NeF requires P,  C3PAse, and C3. Total hemolytic activity was lost by 
incubation of 64 #g of C3NeF/1  ml NHS at 37°C  for 30 rain.  Both C3a and 
C5a anaphylatoxin could be generated by C3NeF in serum previously depleted 
of anaphylatoxin inactivator. Anti-C3NeF  was found  to detect an antigen in 
all NHS tested. Treatment of NHS with solidified anti-C3NeF caused impair- 
ment of the alternate complement pathway. It failed to sustain lysis of gluta- 
thione-treated  human erythrocytes initiated  by inulin.  It is conceivable that 
the  normal  serum  constituent  which  is  removed  by anti-C3NeF  constitutes 
the inactive precursor of C3NeF, and a heretofore unrecognized component of 
the alternate pathway. 
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